40
Participants
Start Date
March 31, 2013
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
Liraglutide
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Placebo
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Liraglutide
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Placebo
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Dept. of Endocrinology, Hvidovre University Hospital, Hvidovre
Collaborators (1)
NNF Center for Basal Metabolic Research, Denmark
UNKNOWN
Hillerod Hospital, Denmark
OTHER
Danish PhD schools of Molecular Metabolism and Endocrinology
OTHER
Novo Nordisk A/S
INDUSTRY
Hvidovre University Hospital
OTHER